Crossmark

The diagnosis and treatment of venous thromboembolism in Asian patients

Crossref DOI link: https://doi.org/10.1186/s12959-017-0155-z

Published Online: 2018-01-18

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Kang-Ling

Yap, Eng Soo

Goto, Shinya

Zhang, Shu

Siu, Chung-Wah

Chiang, Chern-En
Funding

Funding for this research was provided by:

Daiichi-Sankyo
More Information

Article History

Received: 4 August 2017

Accepted: 20 December 2017

First Online: 18 January 2018

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: Kang-Ling Wang has received honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, and Daiichi-Sankyo. Eng Soo Yap has received honoraria from Bayer and Leo Pharma. Chern-En Chiang has been on the speaker bureau for AstraZeneca, Bayer, Boehringer Ingelheim, Chugai, Daiichi-Sankyo, GSK, MSD, Novartis, Pfizer, Roche, Sanofi, Servier, Tanabe, Takeda, and TTY. The other authors report no conflict of interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.